ATHE

Business Context and Reporting Period

Company: Alterity Therapeutics Limited (ASX: ATH; NASDAQ: ATHE)
Reporting Period: Fiscal Year ended June 30, 2024
Business Overview: Alterity is a development-stage biotechnology company focused on treating neurodegenerative diseases, specifically Parkinsonian disorders and Multiple System Atrophy (MSA). The company's lead drug candidate, ATH434, is designed to block the accumulation of alpha-synuclein and restore iron balance in the brain. The company has no commercial products and generates no product revenue.

Key Financial Metrics

Note: All figures are in Australian Dollars (A$). The filing does not provide specific margin data as the company has no revenue.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately A$5.3 million (38%) compared to the prior year, driven primarily by higher R&D expenses.
• R&D Expenses: Increased by A$5.4 million (41.3%) to A$18.6 million, attributable to the conduct of Phase 2 clinical studies for ATH434.
• Operating Cash Flow Improvement: Net cash used in operating activities decreased (improved) by A$7.4 million to A$12.6 million, largely due to the receipt of A$8.6 million in R&D tax incentive refunds.
• Capital Raising: The company raised approximately A$10.1 million through the sale of ordinary shares during the fiscal year, including private placements and an "At-The-Market" (ATM) facility.
• Share Count: Ordinary shares outstanding increased significantly from approximately 2.44 billion to 5.25 billion due to equity issuances.

Guidance, Outlook, and Risks

Going Concern Uncertainty

Management and the auditor have concluded that there is a material uncertainty regarding the company's ability to continue as a going concern. The company has a history of operating losses and will require additional capital to fund its R&D programs. The financial statements are prepared on a going concern basis, assuming the company will successfully raise new equity funding within six months of the year-end.

Clinical Development Outlook

• ATH434-201 (Phase 2 MSA): Enrollment of 77 patients completed in November 2023. Topline data is expected in January 2025.
• ATH434-202 (Phase 2 MSA Biomarker): Positive interim data reported in July 2024 (post-year-end) showed improvement in disability scores and reduced iron accumulation in a subset of participants. Topline data expected in the first half of 2025.
• Future Funding: The company intends to seek additional funding through public/private financings, licensing, or strategic alliances. Failure to secure funding could force delays or elimination of clinical trials.

Key Risks

• Capital Adequacy: Substantial doubt exists regarding the ability to raise necessary capital without significant dilution to shareholders.
• Clinical Trial Failure: Outcomes of clinical trials are uncertain; failure to demonstrate safety or efficacy would halt development.
• Regulatory Approval: No products have been approved; regulatory hurdles remain significant.
• Intellectual Property: Success depends on protecting IP and avoiding infringement of third-party rights.

Investor Verification Checklist

• Cash Runway: Verify the current cash balance and the specific timeline for the next anticipated capital raise to assess immediate liquidity risk.
• Dilution Impact: Review the terms of recent equity issuances and the potential dilution from the 3.25 billion outstanding options and warrants.
• Clinical Trial Status: Confirm the status of the ATH434-201 and ATH434-202 trials and the specific dates for topline data releases.
• R&D Tax Incentive: Verify the timing of the receipt of the A$4.0 million R&D tax incentive receivable recorded in the balance sheet.
• Going Concern Plan: Review management's specific strategy for raising capital within the next six months as disclosed in the filing.